



Clinical Test for Congenital Dislocation of Hip

MOLLAN, RA., Kernohan, G., Richardson, J., Stone, MH., & Bennet, GC. (1987). Clinical Test for Congenital Dislocation of Hip. *Lancet*, 2(8554), 337. [https://doi.org/10.1016/S0140-6736\(87\)90928-7](https://doi.org/10.1016/S0140-6736(87)90928-7)

[Link to publication record in Ulster University Research Portal](#)

Published in:
Lancet

Publication Status:
Published (in print/issue): 01/08/1987


DOI:
[10.1016/S0140-6736\(87\)90928-7](https://doi.org/10.1016/S0140-6736(87)90928-7)

General rights

Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.



Immunohistochemical detection of ANP granules in atrial (A) and ventricular (B) tissues from a patient with dilated cardiomyopathy.

of ANP may possibly be regulated by an overload to which ventricular myofibres are subjected.

Thus even ventricular myocytes may synthesise ANP in special circumstances such as in dilated cardiomyopathy. Because the ventricles are considerably larger than the atria, the total amount of ANP secreted by the ventricle may significantly contribute to high plasma ANP levels in some patients with CHF. The regulation of ANP expression in human ventricles and its relation to pathological changes in patients with CHF and/or dilated cardiomyopathy require further investigation.

Third Department of Internal Medicine,
University of Tokyo,
Hongo, Tokyo 113, Japan;
and Department of Pathology,
Mitsui Memorial Hospital,
Tokyo

HIDETSUGU TSUCHIMOCCHI
YOSHIO YAZAKI
HIDEHITO OHNO
RI-ICHIRO TAKANASHI
FUMIMARO TAKAKU

1. Tikkanen I, Fyhrquist F, Metsärinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. *Lancet* 1985; ii: 66-69.
2. Burnett JC, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. *Science* 1985; 231: 1145-47.
3. Raine AEG, Phil D, Erne P, et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. *N Engl J Med* 1986; 315: 533-37.
4. Latton AL, Michel JB, Armaud E, Corvol P, Soubrier F. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. *Am J Physiol* 1986; 251: H890-96.

ADRENOCEPTORS IN THE DIAGNOSIS OF PHAEOCHROMOCYTOMA

SIR.—Diagnosis of phaeochromocytoma is usually done by the measurement of urinary levels of catecholamines. We have investigated adrenoceptors on membranes of circulating blood components (platelet α_2 -adrenoceptors and leucocyte β -adrenoceptors) in six cases of phaeochromocytoma (four men and two women).

Diagnosis was suspected because of hypertension, and confirmed by high levels of urinary catecholamines and radiological data. In each case, the number of β -adrenoceptor sites (B_{max} assessments with 125 I-cyanopindolol) significantly decreased. B_{max} was 17.7 (SD 4.4) in the patients compared with 48.5 (1.5) fmol/mg protein in six age and sex matched controls ($p < 0.05$, Wilcoxon test). There was no change in affinity constant (Kd). In contrast, there was no significant difference between phaeochromocytoma patients and controls in B_{max} (206.6 [22.6] vs 186.0 [12.1] fmol/mg protein) and Kd values for platelet α_2 -adrenoceptors (measured with 3 H-yohimbine). Catecholamine plasma levels, assayed by HPLC, were wide-ranging in the patients—10.7–172.8 pmol/l for noradrenaline and 0.7–3.9 pmol/l for adrenaline. Plasma dopamine β -hydroxylase activity was normal. Two cases were investigated after tumour removal: catecholamine plasma levels decreased and there was a significant increase in β -adrenoceptor number.

Our study agrees with some data,¹ but not all,² showing that α_2 -adrenoceptors were not altered in platelets of patients with phaeochromocytoma. Human renal or rat cardiac and adipocyte

β -adrenoceptors decrease in phaeochromocytoma.^{1,3} Our work extends this finding to leucocytes. The decrease in leucocyte β -adrenoceptor number is an interesting index in the diagnosis and follow-up after treatment of phaeochromocytoma, because the leucocyte is a suitable and accessible marker. Pharmacologically we conclude that down-regulation occurs in vivo for β -adrenoceptors but not for α_2 -adrenoceptors.

Department of Medical
and Clinical Pharmacology,
Centre Hospitalier Universitaire,
31073 Toulouse, France;
Department of Internal Medicine,
CHU Purpan,
Toulouse;
and Department of Nephrology, CHU Rangueil,
Toulouse

P. VALET
C. DAMASE-MICHEL
B. CHAMONTIN
D. DURAND
G. GAILLARD
M. SALVADOR
J. L. MONTASTRUC

1. Snavely MD, Morulsky HJ, O'Connor DT, Ziegler MG, Insel PA. Adrenergic receptors in human and experimental phaeochromocytoma. *Clin Exp Hyperten* 1982; 4: 829 (abstr).
2. Brödde OE, Bock D. Changes in platelet alpha-2 adrenoceptors in human phaeochromocytoma. *Eur J Clin Pharmacol* 1984; 26: 265.
3. Tsujimoto G, Manger WM, Hoffman BB. Desensitization of beta adrenergic receptor by phaeochromocytoma. *Endocrinology* 1984; 114: 1272.

CLINICAL TEST FOR CONGENITAL DISLOCATION OF HIP

SIR.—Mr Stone and colleagues (April 25, p 954) use a 256 Hz medical tuning-fork to induce vibrations in the patella, and they detect transmission of those vibrations on the symphysis pubis. But control of the input signal in terms of preload and induced frequency thus seems impossible, and the output was subjectively assessed by stethoscope. Can Stone et al demonstrate that the change in signal was due to asymmetry of tissue transmission rather than a difference in support, muscle-tissue tone, limb position, coupling of the input, or subjective bias of the examiner?

An objective test of congenital dislocation needs to be developed to prevent the unacceptable numbers of late presenting dislocation but some control, however small, is needed before this test can be accepted. We hope Stone et al continue their work as we believe that vibration arthrography¹ and transmission² has much to offer in the non-invasive diagnosis of locomotor disease.

Department of Orthopaedic Surgery,
Musgrave Park Hospital,
Belfast BT9 7JB

R. A. MOLLAN
W. G. KERNOHAN

1. Kernohan WG, Beverland DE, McCoy CF, et al. The diagnostic potential of vibration arthrography. *Clin Orthop Related Res* 1986; 210: 106-12.
2. Shaw SN, Elliott JRM, Mollan RAB. The monitoring of fracture healing by vibration transmission. *Proc Specialists' Consensus Meeting, Leuven, 1985: 135-42.*

**This letter has been shown to Mr Richardson and colleagues, whose reply follows.—ED. L.

SIR.—Our study was set up to examine the feasibility of using our technique in any clinical situation, with the most basic of apparatus—namely, a stethoscope and a tuning fork. No attempt was made to control input preload, induced frequencies, or absolute values of output. However, despite these shortcomings our tests picked up 94% of unilateral dislocations tested.

Objective measurements with a variable frequency signal generator and a decibel meter are underway. Preliminary results suggest a loss of transmission of 10 dB in patients with congenital dislocation of the hip.

Using a chicken hip as a model we have found that dislocation, joint effusion, and soft tissue interposition all reduced sound transmission but this was not the case in hip flexion alone.

Our study was done blind and therefore unaffected by examiner bias. Control of muscle tone and limb position is not possible in young children; however, we suggest that this examination is carried out with as contented and comfortable a patient as possible.

We thank Professor Mollan and Dr Kernohan for raising the question of difference in support of the child. We had not considered this factor and hope to include this in further studies.

Accident and Orthopaedic Division,
Royal Infirmary, Glasgow G4 0SF

J. B. RICHARDSON
M. H. STONE
G. C. BENNET